Response to Treatment with Intravenous Golimumab or Infliximab in Rheumatoid Arthritis Patients: PROMIS Results from the Real-World Observational Phase 4 AWARE Study.
Clifton O BinghamShawn BlackNatalie J ShiffStephen XuWayne LangholffJeffrey R Curtis